{"id":4239,"date":"2026-03-09T10:00:40","date_gmt":"2026-03-09T09:00:40","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=4239"},"modified":"2026-02-23T10:25:52","modified_gmt":"2026-02-23T09:25:52","slug":"targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/","title":{"rendered":"Targeted immunocytokines as a neoadjuvant treatment in melanoma"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;Neoadjuvant intralesional darumon, a combination of two fibronectin-targeting immunocytokines, improved recurrence-free survival in patients with locally advanced melanoma&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]<a href=\"https:\/\/www.annalsofoncology.org\/article\/S0923-7534(25)00829-4\/fulltext\" target=\"_blank\" rel=\"noopener\">New data recently published on Annals of Oncology<\/a>\u00a0showed a significantly longer recurrence-free survival than upfront surgery for a neoadjuvant intralesional targeted immunocytokines treatment in patients with locally advanced melanoma.<\/p>\n<p>The PIVOTAL trial is an open-label, randomized, controlled, multicenter phase III trial involving a total of 246 patients with clinically detectable stage III melanoma; participants were randomized to receive weekly intralesional daromun administrations for 4 weeks before surgery or upfront surgery. At a median follow-up of 21 months, recurrence-free survival was 16.7 months for darumon group and 6.8 months for upfront surgery: the risk of distant recurrence was reduced by 40% in the neoadjuvant arm. Treatment-related adverse effects were more frequent in darumon group but they were moslty injection site reactions. As authors point out, \u00abNeoadjuvant and perioperative immunotherapies are gaining ground in clinical practice for resectable stage III melanoma. Patients who receive neoadjuvant therapy are at risk of losing the opportunity for curative surgery due to disease progression or treatment-related serious adverse events before surgery; however only 4.9% of patients in the neoadjuvant daromun arm experienced disease progression or adverse events leading to inability to undergo surgery, moreover daromun was well tolerated. \u00a0In contrast to systemic neoadjuvant regimens, which have reported grade \u22653 adverse events in up to 47% of patients, daromun demonstrated a favorable safety profile with significantly lower rates of high-grade toxicity (28.8%) and serious adverse events (10.2%). Thus neoadjuvant daromun represents a well-tolerated and effective therapeutic option for patients with pretreated, recurrent stage III melanoma. Its favorable safety profile and clinical efficacy support its potential role as a complementary or alternative strategy to systemic immunotherapy, particularly in high-risk patients or those ineligible for immune checkpoint inhibitors\u00bb.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;4271&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;Neoadjuvant intralesional darumon, a combination of two fibronectin-targeting immunocytokines, improved recurrence-free survival in patients with locally advanced melanoma&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]New data recently published on<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":4271,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-4239","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Targeted immunocytokines as a neoadjuvant treatment in melanoma - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"Neoadjuvant intralesional darumon, a combination of two fibronectin-targeting immunocytokines, improved recurrence-free survival in patients with locally advanced melanoma\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Targeted immunocytokines as a neoadjuvant treatment in melanoma - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"Neoadjuvant intralesional darumon, a combination of two fibronectin-targeting immunocytokines, improved recurrence-free survival in patients with locally advanced melanoma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T09:00:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/03\/Image_AnnalsOncology_09Mar26-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1589\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"Targeted immunocytokines as a neoadjuvant treatment in melanoma\",\"datePublished\":\"2026-03-09T09:00:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\\\/\"},\"wordCount\":345,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Image_AnnalsOncology_09Mar26-scaled.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\\\/\",\"name\":\"Targeted immunocytokines as a neoadjuvant treatment in melanoma - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Image_AnnalsOncology_09Mar26-scaled.jpg\",\"datePublished\":\"2026-03-09T09:00:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"Neoadjuvant intralesional darumon, a combination of two fibronectin-targeting immunocytokines, improved recurrence-free survival in patients with locally advanced melanoma\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Image_AnnalsOncology_09Mar26-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Image_AnnalsOncology_09Mar26-scaled.jpg\",\"width\":2560,\"height\":1589},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Targeted immunocytokines as a neoadjuvant treatment in melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Targeted immunocytokines as a neoadjuvant treatment in melanoma - Fondazione Gianni Bonadonna","description":"Neoadjuvant intralesional darumon, a combination of two fibronectin-targeting immunocytokines, improved recurrence-free survival in patients with locally advanced melanoma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"Targeted immunocytokines as a neoadjuvant treatment in melanoma - Fondazione Gianni Bonadonna","og_description":"Neoadjuvant intralesional darumon, a combination of two fibronectin-targeting immunocytokines, improved recurrence-free survival in patients with locally advanced melanoma","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2026-03-09T09:00:40+00:00","og_image":[{"width":2560,"height":1589,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/03\/Image_AnnalsOncology_09Mar26-scaled.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"Targeted immunocytokines as a neoadjuvant treatment in melanoma","datePublished":"2026-03-09T09:00:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/"},"wordCount":345,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/03\/Image_AnnalsOncology_09Mar26-scaled.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/","name":"Targeted immunocytokines as a neoadjuvant treatment in melanoma - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/03\/Image_AnnalsOncology_09Mar26-scaled.jpg","datePublished":"2026-03-09T09:00:40+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"Neoadjuvant intralesional darumon, a combination of two fibronectin-targeting immunocytokines, improved recurrence-free survival in patients with locally advanced melanoma","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/03\/Image_AnnalsOncology_09Mar26-scaled.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/03\/Image_AnnalsOncology_09Mar26-scaled.jpg","width":2560,"height":1589},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Targeted immunocytokines as a neoadjuvant treatment in melanoma"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=4239"}],"version-history":[{"count":5,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4239\/revisions"}],"predecessor-version":[{"id":4277,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4239\/revisions\/4277"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/4271"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=4239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=4239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=4239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}